Home
Subscription
April 2024 issue
April 1, 2024 issue
March 2024 issue
February 2024 issue
January 2024 issue
BACK ISSUES
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
|
2019 Issues
December 2019 Issue
• Feature: Importing Drugs from Canada is a Flawed "Solution" for Failures in the U.S.
• New Drug Review: Lefamulin acetate (Xenleta)
• Appreciation
• Index for Volume 14, 2019
November 2019 Issue
• Feature: CIGARETTES AND VAPING PRODUCTS - MUCH SMOKE AND RHETORIC, BUT NO ACTION
• New Drug Review: Omadacycline tosylate (Nuzyra)
October 2019 Issue
• Feature: CANNABIS CHAOS
• New Drug Review: Cannabidiol (Epidiolex)
September 2019 Issue
• Feature: Are Generics Really the Same as Brand-Name Medicines?
• New Drug Review: Prucalopride succinate (Motegrity)
August 2019 Issue
• Feature: Judge Richard Leon and CVS
July 2019 Issue
• Feature: Walmart Should Get Out of Pharmacy!
• Table: New Therapeutic Agents Marketed in the United States in 2018
June 2019 Issue
• Feature: They Must be Anonymous, But They Will Not be Silent!
• New Drug Review: Revefenacin (Yupelri)
• Rays of Hope: Congratulations to Mayank Amin and Skippack Pharmacy!
May 2019 Issue
• Feature: "I believe I am a danger to the public working for CVS."
• New Drug Review: Lofexidine hydrochloride (Lucemyra)
Easter 2019 Issue
• Feature: FDA BANS SALE OF NICOTINE!
April 1, 2019 Issue
• Feature: FDA BANS SALE OF NICOTINE!
March 2019 Issue
• Feature: Society, Patients, and our Profession Need Independent Pharmacists!
CHALLENGES AND STRATEGIES
• New Drug Review: Elagolix sodium (Orilissa)
February 2019 Issue
• Feature: CVS-Aetna (continued)
January 2019 Issue
• Feature: Reducing Drug Prices – By Increasing Competition, Increasing Self-care, and Eliminating PBM Fraud and Scams
• New Drug Review: Galcanezumab-gnlm (Emgality)
| |
